Philip Muller, DO
Psychiatry · Sioux City, IANPI 1891756128
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$891
- Johnson & Johnson$752
- Alkermes, Inc.$691
- Vanda Pharmaceuticals Inc.$563
- Lundbeck LLC$470
- AbbVie$453
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,22699%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 59 | $891 |
| Johnson & Johnson | 42 | $752 |
| Alkermes, Inc. | 36 | $691 |
| Vanda Pharmaceuticals Inc. | 26 | $563 |
| Lundbeck LLC | 24 | $470 |
| AbbVie(2 entities) | 37 | $453 |
| Teva Pharmaceuticals USA, Inc. | 25 | $453 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $423 |
| Sunovion Pharmaceuticals Inc. | 15 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $213 |
| E.r. Squibb & Sons, L.L.C. | 15 | $199 |
| Supernus Pharmaceuticals, Inc. | 7 | $197 |
| Neurocrine Biosciences, Inc. | 10 | $139 |
| Corium, LLC | 7 | $97 |
| Shire North American Group Inc | 5 | $64 |
| Noven Therapeutics, LLC | 4 | $64 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Bioxcel Therapeutics, Inc. | 3 | $54 |
| Almatica Pharma LLC | 2 | $46 |
| Indivior Inc. | 2 | $45 |
| Ironshore Pharmaceuticals Inc. | 3 | $42 |
| Avanir Pharmaceuticals, Inc. | 3 | $35 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Neos Therapeutics, LP | 2 | $30 |
| Merck | 2 | $29 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$101
How this compares
$6,279 in reported general payments places this provider in the 90th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 53 | $142,339 |
| IngrezzaValbenazine Tosylate | 11 | $88,182 |
| VraylarCariprazine Hcl | 38 | $47,065 |
| Abilify MaintenaAripiprazole | 13 | $38,652 |
| Lurasidone Hcl | 87 | $30,611 |
| Aripiprazole | 131 | $12,802 |
| AbilifyAripiprazole | 13 | $11,199 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,542 |
| Clozapine | 117 | $5,971 |
| TrintellixVortioxetine Hydrobromide | 16 | $5,572 |
| Quetiapine Fumarate | 332 | $4,382 |
| Olanzapine | 106 | $3,533 |
| Fluvoxamine Maleate | 54 | $3,482 |
| Bupropion XlBupropion Hcl | 232 | $3,405 |
| Clomipramine Hcl | 31 | $2,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $752 | $142,33953 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $139 | $88,18211 claims |
| AbbVieVraylar | $453 | $47,06538 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $891 | $38,65213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $213 | $13,11336 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $199 | $11,19913 claims |
| Almatica Pharma LLCSertraline Hcl | $46 | $1,589164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Sioux City
- Rodney DeanSioux City$11K
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
- Alan WhittersCedar Rapids$170K
- Donald BlackIowa City$19K
- William CoryellIowa City$18K
- Randall KavalierWest Des Moines$15K
- Dwight SchroederCedar Rapids$13K
- Peggy NopoulosIowa City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.